Portal de Periódicos da CAPES

The Impact of Hyperuricemia on Patients With Low Body Mass Index After Endovascular Treatments: Data From the I-PAD Registry

2022; SAGE Publishing; Volume: 73; Issue: 8 Linguagem: Inglês

10.1177/00033197211072344

1940-1574

Ayumu Nagae, Soichiro Ebisawa, Tatsuya Saigusa, Ken Nishikawa, Koki Fujimori, Hisanori Yui, Shusaku Maruyama, Chié Nakamura, Daisuke Kashiwagi, Hideki Kobayashi, Takahiro Sakai, Keisuke Senda, Tamon Kato, Takashi Miura, Ayako Okada, Hirohiko Motoki, Koichiro Kuwahara,

Case Reports on Hematomas

We investigated the prognostic effects of hyperuricemia and high or low body mass index (BMI) in peripheral artery disease (PAD) after endovascular therapy (EVT). Between July 2015-2016, 357 consecutive patients with PAD who underwent EVT were enrolled. Patients were divided into 2 groups: BMI < 25 kg/m2 (low BMI) and ≥ 25 kg/m2 (high BMI); they were also divided into 2 more groups based on the presence/absence of hyperuricemia. The primary and secondary endpoints were major adverse cardiovascular and limb events (MACLE), and all-cause death at 3 years post-EVT. Patients with hyperuricemia had significantly lower freedom from MACLE than patients without hyperuricemia at 3 years (57.0 vs 71.9%, p = .0068). The overall survival of patients with hyperuricemia was significantly lower than that of patients without hyperuricemia (63.9 vs 81.7%, p = .0012). Patients with hyperuricemia who had low BMI experienced significantly lower freedom from MACLE than those without hyperuricemia who had low BMI (48.2 vs 69.9%, p = .002). The overall survival of patients with hyperuricemia who had low BMI was significantly lower than that of patients without hyperuricemia who had low BMI (55.2 vs 77.1%, p = .003). Patients with hyperuricemia had significantly more MACLE and a lower survival at 3 years than patients without hyperuricemia, even if they had a low BMI.